Eton Pharmaceuticals (NASDAQ:ETON) Trading 5.9% Higher – Should You Buy?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares were up 5.9% during trading on Thursday . The company traded as high as $59.10 and last traded at $58.8930. 396,284 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 430,245 shares. The stock had previously closed at $55.61.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ETON shares. Canaccord Genuity Group upped their target price on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. HC Wainwright lifted their target price on Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.50.

Eton Pharmaceuticals Price Performance

The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The company’s fifty day moving average price is $52.92 and its 200 day moving average price is $37.17. The company has a market capitalization of $1.68 billion, a P/E ratio of 154.75 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The business had revenue of $37.59 million for the quarter, compared to the consensus estimate of $27.11 million. As a group, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current year.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the sale, the director directly owned 59,745 shares in the company, valued at $3,529,137.15. This represents a 45.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David Krempa sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the transaction, the insider owned 37,025 shares of the company’s stock, valued at $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 16.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $68,629,000. EcoR1 Capital LLC raised its holdings in shares of Eton Pharmaceuticals by 7.0% during the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after buying an additional 141,394 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth $42,569,426. Pillsbury Lake Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth $14,015,083. Finally, Panoramic Capital LLC acquired a new stake in Eton Pharmaceuticals in the second quarter valued at about $7,537,000. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for underserved patient populations, with an emphasis on pediatric, rare disease and other difficult-to-treat conditions. The company generally pursues products with established clinical or regulatory pathways and works to bring them to market through its own commercial operations or strategic partnerships.

Eton’s marketed portfolio includes Eprontia, an oral solution formulation of topiramate used in the treatment of certain seizure disorders; Biorphen, an injectable phenylephrine product used to treat clinically important low blood pressure; and Alkindi Sprinkle, a hydrocortisone granule product for replacement therapy in children with adrenal insufficiency.